Ligand Pharmaceuticals Incorporated filed a Form 8-K on September 22, 2026, disclosing that it acquired royalty and milestone payment rights relating to Santen Pharmaceutical Co., Ltd.'s Ryjunea® from Sydnexis, Inc. for $23 million upfront.
Key Highlights
- Acquisition price: Ligand paid $23 million upfront for the rights.
- Rights acquired: Royalty and milestone payment rights relating to Ryjunea®, a product of Santen Pharmaceutical Co., Ltd.
- Seller: The rights were acquired from Sydnexis, Inc.
- Disclosure date: The press release announcing the transaction was issued on September 22, 2026.
- Listing: Ligand's common stock, par value $0.001 per share, trades on The Nasdaq Global Market under the symbol LGND.
Ligand Acquires Santen's Ryjunea Royalty and Milestone Rights from Sydnexis
According to the filing, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced on September 22, 2026, that it had acquired royalty and milestone payment rights relating to Santen Pharmaceutical Co., Ltd.'s Ryjunea® from Sydnexis, Inc. The company disclosed that the upfront consideration for the transaction was $23 million. The filing did not specify additional terms, contingent payments beyond those described as milestone rights, or details regarding the expected timing of any such milestones.
The disclosure was made under Item 7.01, Regulation FD, of the Form 8-K. The filing noted that the information furnished under this item, including the press release attached as Exhibit 99.1, "shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended." The press release, dated September 22, 2026, was incorporated into the filing by reference and described as containing "certain other information regarding the Transaction," though the body of the press release itself was not reproduced within the 8-K text provided.
The report was signed by Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Incorporated, on September 22, 2026. Ligand is incorporated in Delaware and maintains its principal executive offices at 555 Heritage Drive, Suite 200, Jupiter, Florida 33458.
What Was Disclosed
Ligand Pharmaceuticals disclosed via an 8-K filed September 22, 2026, that it acquired royalty and milestone payment rights for Ryjunea® from Sydnexis, Inc. for $23 million upfront. A supporting press release was furnished as Exhibit 99.1.



Please wait processing your request...